ERBB2 and gastric cancer: However, these biomarkers have to be validated in human clinical trial studies. In addition, HER2-positive GC patients who were previously treated with anti-HER2 therapy should be inspected for HER2-positive status before the administration of second-line anti-HER2 TKIs.